|
US2020318113A1
|
|
Polynucleotide conjugates and uses thereof
|
|
WO2020181107A1
|
|
Microrna mimics and uses thereof
|
|
WO2020117312A1
|
|
Treatment of adult t cell leukemia/lymphoma (atll) using mir-155 inhibitors
|
|
KR20200093611A
|
|
MiR29 mimic for treatment of ocular fibrosis
|
|
WO2018183127A1
|
|
Mir-92 inhibitors for treatment of heart failure
|
|
US2020276220A1
|
|
Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitors
|
|
US2018250325A1
|
|
Mir-19 modulators and uses thereof
|
|
NZ737542A
|
|
Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
|
|
CN107922947A
|
|
For treating 155 inhibitor of MIR of amyotrophic lateral sclerosis (ALS)
|
|
WO2016149370A1
|
|
Mirna mimetics and their use in treating sensory conditions
|
|
SG11201705907XA
|
|
Mir-92 inhibitors and uses thereof
|
|
WO2016069717A1
|
|
Inhibitors of mirnas in regulation of arterial stiffness and uses thereof
|
|
AU2015315298A1
|
|
miR-29 mimics and uses thereof
|
|
CN108064175A
|
|
Inhibitor of MYH7B and application thereof
|
|
US2017073368A1
|
|
Synthesis of bicyclic nucleosides
|
|
AU2014233115A1
|
|
Bridged bicyclic nucleosides
|
|
CN105188715A
|
|
Locked nucleic acid inhibitor of miR-145 and uses thereof
|
|
NZ728207A
|
|
Oligonucleotide-based inhibitors comprising locked nucleic acid motif
|
|
AU2013278011A1
|
|
Oligonucleotide-based inhibitors comprising locked nucleic acid motif
|
|
EP2763703A2
|
|
Control of whole body energy homeostasis by microrna regulation
|
